The following adverse reactions have been reported from worldwide marketing experience with tacrolimus. Because these reactions are reported voluntarily from a population of uncertain size it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of the reporting, or (3) strength of causal connection to the drug.
Other reactions include:
- Atrial fibrillation, atrial flutter, cardiac arrhythmia, cardiac arrest, electrocardiogram T wave abnormal, flushing, myocardial infarction, myocardial ischemia, pericardial effusion, QT prolongation, Torsade de Pointes , venous thrombosis deep limb, ventricular extrasystoles, ventricular fibrillation, myocardial hypertrophy [see Warnings and Precautions ( 5.13)]
- Bile duct stenosis, colitis, enterocolitis, gastroenteritis, gastroesophageal reflux disease, hepatic cytolysis, hepatic necrosis, hepatotoxicity, impaired gastric emptying, liver fatty, mouth ulceration, pancreatitis hemorrhagic, pancreatitis necrotizing, stomach ulcer, veno-occlusive liver disease
- Agranulocytosis, disseminated intravascular coagulation, hemolytic anemia, neutropenia, febrile neutropenia, pancytopenia, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, pure red cell aplasia [see Warnings and Precautions ( 5.15)]
- Cases of progressive multifocal leukoencephalopathy (PML), sometimes fatal; polyoma virus-associated nephropathy, (PVAN) including graft loss [see Warnings and Precautions ( 5.2)]
- Glycosuria, increased amylase including pancreatitis, weight decreased
- Feeling hot and cold, feeling jittery, hot flushes, multi-organ failure, primary graft dysfunction
- Musculoskeletal and Connective Tissue Disorders
- Pain in extremity including Calcineurin-Inhibitor Induced Pain Syndrome (CIPS)
- Nervous System
- Carpal tunnel syndrome, cerebral infarction, hemiparesis, leukoencephalopathy, mental disorder, mutism, posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions ( 5.6)], progressive multifocal leukoencephalopathy (PML) [see Warnings and Precautions ( 5.2)] , quadriplegia, speech disorder, syncope
- Acute respiratory distress syndrome, interstitial lung disease, lung infiltration, respiratory distress, respiratory failure
- Stevens-Johnson syndrome, toxic epidermal necrolysis
- Special Senses
- Blindness, optic neuropathy, blindness cortical, hearing loss including deafness, photophobia
- Acute renal failure, cystitis hemorrhagic, hemolytic-uremic syndrome
When tacrolimus is prescribed with a given dose of a mycophenolic acid (MPA) product, exposure to MPA is higher with tacrolimus co-administration than with cyclosporine co-administration with MPA, because cyclosporine interrupts the enterohepatic recirculation of MPA while tacrolimus does not. Monitor for MPA associated adverse reactions and reduce the dose of concomitantly administered mycophenolic acid products as needed.
Table 15 displays the effects of other drugs on tacrolimus.
| || || |
| || |
| || |
Other drugs, such as:
| || |
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.